Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Veterinary Orodispersible Tablets Market Forecast: Value Set To Climb From $1.21 Billion To $1.65 Billion
The veterinary orodispersible tablets market has experienced substantial growth in recent years. Its value is projected to climb from $1.12 billion in 2025 to $1.21 billion in 2026, driven by a compound annual growth rate (CAGR) of 7.9%. Historically, this growth has been influenced by factors such as poor medication compliance in companion animals, the difficulties involved in orally dosing traditional veterinary tablets, the restricted availability of palatable veterinary formulations, a dependence on conventional solid oral dosage forms, and a lack of advanced drug delivery technologies in veterinary medicine.
The market for veterinary orodispersible tablets is projected to experience substantial expansion in the coming years. This sector is anticipated to reach a valuation of $1.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This anticipated growth is driven by several factors, including increasing consumer demand for convenient pet medication forms, the rising uptake of precision drug delivery methods, an increase in spending on companion animal healthcare, innovations in veterinary pharmaceutical formulations, and a greater emphasis on ensuring treatment adherence and ease of administration. Key trends anticipated during this period involve the creation of taste-masked formulations to enhance the palatability of veterinary orodispersible tablets, the growing use of rapidly disintegrating polymer matrices for improved drug dissolution in animal oral delivery, an uptick in the application of precisely compounded low-dose orodispersible tablets for companion animal treatments, the increasing incorporation of advanced excipient engineering to boost stability and disintegration speed in veterinary tablets, and the broader implementation of stress-free pet medication delivery systems to improve treatment compliance in animals.
Get A Free Sample Report With In-Depth Market Insights:
Veterinary Orodispersible Tablets Market Growth Catalysts And Demand Drivers
The growing expenditure by pet owners on companion-animal healthcare is anticipated to boost the growth of the veterinary orodispersible tablets market. This spending refers to the total financial investment by individuals in veterinary services, preventive care, treatments, and related health products for their pets. The increase in this spending is expanding due to the rising perception of pets as family members, which encourages owners to invest more in preventive care, advanced treatments, and overall well-being. This rising demand for companion-animal healthcare spending by pet owners drives the adoption of veterinary orodispersible tablets, as these convenient and palatable formulations improve compliance, ensure accurate dosing, and support the growing focus on pet wellness and preventive care. For instance, in March 2025, according to the American Pet Products Association (APPA), a US-based trade association for the pet industry, total US pet industry expenditures reached $147 billion in 2023, rising further to $152 billion in 2024, reflecting continued year-over-year growth. Therefore, expanding companion-animal healthcare spending by pet owners is driving the growth of the veterinary orodispersible tablets market. The increasing pet ownership worldwide is anticipated to drive the growth of the veterinary orodispersible tablets market in the future. Global pet ownership refers to the proportion of households around the globe that keep companion animals, reflecting their widespread prevalence and cultural adoption across different regions. This increase in global pet ownership is attributed to the growing trend of viewing pets as family members, which motivates individuals and households to adopt companion animals for companionship, emotional support, and lifestyle enrichment. The rising global pet ownership fuels demand for veterinary orodispersible tablets, as a larger companion-animal population increases the need for convenient, palatable, and easily administered medications to ensure health, compliance, and overall well-being. For instance, in March 2025, according to the American Pet Products Association, a US-based non-profit association, currently, 94 million households in the U. S. own at least one pet, marking an increase from 82 million households in 2023. Therefore, rising pet ownership globally is driving the growth of the veterinary orodispersible tablets market.
Veterinary Orodispersible Tablets Market Segment Analysis Spotlighting Growth Areas
The veterinary orodispersible tablets market covered in this report is segmented –
1) By Product Type: Analgesics, Antibiotics, Anthelmintics, Antipyretics, Other Product Types
2) By Animal Type: Companion Animals, Livestock Animals, Other Animal Types
3) By Application: Infectious Diseases, Pain Management, Gastrointestinal Disorders, Other Applications
4) By End User: Veterinary Clinics, Veterinary Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Analgesics: Non Steroidal Anti Inflammatory Analgesics, Opioid Analgesics, Local Analgesics, Combination Analgesics, Herbal Analgesics
2) By Antibiotics: Beta Lactam Antibiotics, Tetracycline Antibiotics, Aminoglycoside Antibiotics, Macrolide Antibiotics, Fluoroquinolone Antibiotics
3) By Anthelmintics: Benzimidazole Anthelmintics, Macrocyclic Lactone Anthelmintics, Imidazothiazole Anthelmintics, Praziquantel Based Anthelmintics, Combination Anthelmintics
4) By Antipyretics: Non Steroidal Anti Inflammatory Antipyretics, Acetaminophen Based Antipyretics, Aspirin Based Antipyretics, Herbal Antipyretics, Combination Antipyretics
5) By Other Product Types: Antihistamines, Vitamins And Supplements, Probiotics, Cardiovascular Agents, Respiratory Agents
Veterinary Orodispersible Tablets Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the veterinary orodispersible tablets market are Zoetis Inc., Elanco Animal Health Incorporated, Ceva Santé Animale S. A., Merck & Co. Inc., Virbac S. A., Phibro Animal Health Corporation, HIPRA S. A., Vetoquinol S. A., Norbrook Laboratories Limited, KRKA d. d. Novo mesto, Intas Pharmaceuticals Limited, Boehringer Ingelheim Animal Health GmbH, Hester Biosciences Limited, Huvepharma EOOD, AdvaCare Pharma, ODT Pharmaceuticals Inc., Provet Pharma Private Limited, Kyoritsu Seiyaku Corporation, Ani Healthcare Private Limited, Vee Remedies Private Limited, Skyec Drugs and Pharmaceuticals Private Limited, Dotcom Pharma Private Limited, Alicanto Vetcare Private Limited, Vetraise Remedies Private Limited, Vetson Healthcare Private Limited
View The Full Veterinary Orodispersible Tablets Market Report:
Veterinary Orodispersible Tablets Market Geographic Distribution And Regional Opportunities
North America was the largest region in the veterinary orodispersible tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary orodispersible tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.